Like_老虎社区_美港股上老虎

NeM0ooo
2021-12-24

NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News<blockquote>NVAX股票：关于Novavax抗击奥密克戎新闻需要了解的5件事</blockquote>

The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday se

NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News<blockquote>NVAX股票：关于Novavax抗击奥密克戎新闻需要了解的5件事</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":698104879,"tweetId":"698104879","gmtCreate":1640313182480,"gmtModify":1640313845837,"author":{"id":4091976027440070,"idStr":"4091976027440070","authorId":4091976027440070,"authorIdStr":"4091976027440070","name":"NeM0ooo","avatar":"https://static.tigerbbs.com/fc945b6e362666c4cb11d3c9b09018e8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698104879","repostId":1135530287,"repostType":4,"repost":{"id":"1135530287","kind":"news","pubTimestamp":1640312913,"share":"https://www.laohu8.com/m/news/1135530287?lang=zh_CN&edition=full","pubTime":"2021-12-24 10:28","market":"us","language":"en","title":"NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News<blockquote>NVAX股票：关于Novavax抗击奥密克戎新闻需要了解的5件事</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1135530287","media":"InvestorPlace","summary":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday se","content":"<p><div> The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p><p><blockquote><div>随着人们准备庆祝假期，奥密克戎变种没有显示出放缓的迹象。本周早些时候，疾病预防控制中心报告说，奥密克戎现在是美国主要的冠状病毒株...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News<blockquote>NVAX股票：关于Novavax抗击奥密克戎新闻需要了解的5件事</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News<blockquote>NVAX股票：关于Novavax抗击奥密克戎新闻需要了解的5件事</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-12-24 10:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p><p><blockquote><div>随着人们准备庆祝假期，奥密克戎变种没有显示出放缓的迹象。本周早些时候，疾病预防控制中心报告说，奥密克戎现在是美国主要的冠状病毒株...</div></blockquote></p><p>  <a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135530287","content_text":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.\nNovavax(NASDAQ:NVAX) recently reported the initial results of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.\nNovavax’s President of Research and Development Gregory Glenn added that:\n\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n\nIn recent Novavax news, its vaccine was granted approval for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.\nWith the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.\nNVAX Stock: 5 Things to Know\n\nAfter two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.\nNovavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.\nAdditionally, the vaccine maker has plans to ship 200 million doses to the E.U.\nGlenn remarked that “Given the continued evolution of the coronavirus, the development of an omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”\nNovavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":3035,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}